Home LiteratureArticle Details
PMID: 7969121 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Molecular and cellular biology ·Vol. 14 ·No. 12 ·1994-12-00 ·Pages 7805-15

Roy B, Beamon J, Balint E, Reisman D

Abstract

Elevated levels of mutant forms of the p53 tumor suppressor are a hallmark of many transformed cells. Multiple mechanisms such as increased stability of the protein and increased transcription of the gene can account for elevated p53 expression. Recent findings indicate that c-Myc/Max heterodimers can bind to an essential CA(C/T)GTG-containing site in the p53 promoter and elevate its expression. We have addressed the possibility that elevated mutant p53 expression is due to deregulated c-Myc expression. Here we demonstrate that the human p53 promoter is transactivated by high c-Myc expression and repressed by high Max expression. In examining the relative levels of c-Myc and p53 in human Burkitt's lymphomas and other B-lymphoid lines, we found that there is a correlation between the levels of c-Myc protein and p53 mRNA expression. In particular, cells that express very low levels of c-Myc protein also express low levels of p53 mRNA, while cells that express high levels of c-Myc tend to express high levels of p53 mRNA. To determine whether the p53 gene can be a target for c-Myc in vivo, we assayed the effects of antisense c-myc RNA on the levels of endogenous p53 mRNA. The results indicate that the presence of antisense c-myc RNA leads to a reduction in the levels of c-Myc protein, p53 mRNA, and expression from the p53 promoter. Taken together, our findings support a direct role for c-Myc in elevating expression of the mutant p53 gene in some tumors.

Related Genes
MeSH Terms
Animals Basic Helix-Loop-Helix Leucine Zipper Transcription Factors Basic-Leucine Zipper Transcription Factors Binding Sites Burkitt Lymphoma/genetics Cell Line Chlorocebus aethiops DNA-Binding Proteins/physiology Gene Expression Regulation, Neoplastic Genes, myc Genes, p53 Humans In Vitro Techniques Promoter Regions, Genetic Proto-Oncogene Proteins c-myc/physiology RNA, Neoplasm/genetics Transcription Factors Transcription, Genetic Transcriptional Activation Tumor Suppressor Protein p53/genetics
Chemicals
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors Basic-Leucine Zipper Transcription Factors DNA-Binding Proteins MAX protein, human Myc associated factor X Proto-Oncogene Proteins c-myc RNA, Neoplasm Transcription Factors Tumor Suppressor Protein p53
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Roy B
Department of Biological Sciences, University of South Carolina, Columbia 29208.
Beamon J
Balint E
Reisman D
References (92)
92 references, click to expand
  1. Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
    Oncogene. 1990 Aug;5(8):1187-93 PMID: 1697409
  2. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  3. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  4. An amino-terminal c-myc domain required for neoplastic transformation activates transcription.
    Mol Cell Biol. 1990 Nov;10(11):5914-20 PMID: 2233723
  5. Negative autoregulation of c-myc gene expression is inactivated in transformed cells.
    EMBO J. 1990 Dec;9(12):3913-22 PMID: 2249657
  6. Sequence-specific DNA binding by the c-Myc protein.
    Science. 1990 Nov 23;250(4984):1149-51 PMID: 2251503
  7. Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression.
    Oncogene. 1990 Nov;5(11):1701-6 PMID: 2267136
  8. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells.
    Oncogene. 1990 Nov;5(11):1707-11 PMID: 2267137
  9. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region.
    Science. 1991 Jan 11;251(4990):186-9 PMID: 1987636
  10. Genetic mechanisms of tumor suppression by the human p53 gene.
    Science. 1990 Dec 14;250(4987):1576-80 PMID: 2274789
  11. p53 mutations: gains or losses?
    J Cell Biochem. 1991 Jan;45(1):22-9 PMID: 2005181
  12. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
    Science. 1991 Mar 8;251(4998):1211-7 PMID: 2006410
  13. Mutational hotspot in the p53 gene in human hepatocellular carcinomas.
    Nature. 1991 Apr 4;350(6317):427-8 PMID: 1849234
  14. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.
    Nature. 1991 Apr 4;350(6317):429-31 PMID: 1672732
  15. Control of c-myc regulation in normal and neoplastic cells.
    Adv Cancer Res. 1991;56:1-48 PMID: 2028839
  16. Expression from the murine p53 promoter is mediated by factor binding to a downstream helix-loop-helix recognition motif.
    Proc Natl Acad Sci U S A. 1991 May 15;88(10):4128-32 PMID: 1851994
  17. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  18. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  19. The MCK enhancer contains a p53 responsive element.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4570-1 PMID: 1647009
  20. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
    Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 PMID: 2052620
  21. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
  22. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.
    Nature. 1991 Jul 25;352(6333):345-7 PMID: 1852210
  23. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
    Cancer Res. 1991 Oct 1;51(19):5232-7 PMID: 1717142
  24. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.
    EMBO J. 1992 Apr;11(4):1383-90 PMID: 1314165
  25. max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors.
    Oncogene. 1992 Apr;7(4):775-9 PMID: 1565473
  26. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.
    Nature. 1992 May 7;357(6373):82-5 PMID: 1533443
  27. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.
    Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9 PMID: 1584781
  28. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Science. 1992 May 8;256(5058):827-30 PMID: 1589764
  29. p53 is frequently mutated in Burkitt's lymphoma cell lines.
    EMBO J. 1991 Oct;10(10):2879-87 PMID: 1915267
  30. Involvement of wild-type p53 in pre-B-cell differentiation in vitro.
    Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8982-6 PMID: 1924360
  31. Participation of p53 protein in the cellular response to DNA damage.
    Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 PMID: 1933891
  32. Analysis of p53 mutants for transcriptional activity.
    Mol Cell Biol. 1991 Dec;11(12):6067-74 PMID: 1944276
  33. Wild-type p53 can down-modulate the activity of various promoters.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9979-83 PMID: 1946467
  34. Max: functional domains and interaction with c-Myc.
    Genes Dev. 1992 Jan;6(1):81-92 PMID: 1730412
  35. Induction of apoptosis in fibroblasts by c-myc protein.
    Cell. 1992 Apr 3;69(1):119-28 PMID: 1555236
  36. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
    Nature. 1993 Apr 29;362(6423):857-60 PMID: 8479525
  37. Definition of a consensus binding site for p53.
    Nat Genet. 1992 Apr;1(1):45-9 PMID: 1301998
  38. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.
    Nature. 1993 May 20;363(6426):281-3 PMID: 8387645
  39. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.
    Cell Growth Differ. 1993 Feb;4(2):57-65 PMID: 8494784
  40. The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription.
    Mol Cell Biol. 1993 Jun;13(6):3291-300 PMID: 8497252
  41. Gain of function mutations in p53.
    Nat Genet. 1993 May;4(1):42-6 PMID: 8099841
  42. The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication.
    Cell. 1993 Jun 18;73(6):1207-21 PMID: 8390328
  43. The p53-mdm-2 autoregulatory feedback loop.
    Genes Dev. 1993 Jul;7(7A):1126-32 PMID: 8319905
  44. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.
    Mol Cell Biol. 1993 Sep;13(9):5186-94 PMID: 8355677
  45. Binding of myc proteins to canonical and noncanonical DNA sequences.
    Mol Cell Biol. 1993 Sep;13(9):5216-24 PMID: 8395000
  46. The ornithine decarboxylase gene is a transcriptional target of c-Myc.
    Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8 PMID: 8356088
  47. Inhibition of DNA replication factor RPA by p53.
    Nature. 1993 Sep 2;365(6441):79-82 PMID: 8361542
  48. Direct role for Myc in transcription initiation mediated by interactions with TFII-I.
    Nature. 1993 Sep 23;365(6444):359-61 PMID: 8377829
  49. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein.
    Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8489-93 PMID: 7690963
  50. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
    Nat Genet. 1993 Sep;5(1):56-61 PMID: 8220424
  51. An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence.
    Genes Dev. 1992 Dec;6(12B):2513-23 PMID: 1340466
  52. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes?
    Cell. 1993 Nov 19;75(4):765-78 PMID: 8242748
  53. WAF1, a potential mediator of p53 tumor suppression.
    Cell. 1993 Nov 19;75(4):817-25 PMID: 8242752
  54. Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc.
    Science. 1993 Dec 17;262(5141):1889-92 PMID: 8266081
  55. An E-box element localized in the first intron mediates regulation of the prothymosin alpha gene by c-myc.
    Mol Cell Biol. 1994 Jun;14(6):3853-62 PMID: 8196628
  56. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
    Science. 1994 Jul 15;265(5170):346-55 PMID: 8023157
  57. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.
    Cell. 1983 Dec;35(3 Pt 2):603-10 PMID: 6606489
  58. Growth regulation of a cellular tumour antigen, p53, in nontransformed cells.
    Nature. 1984 Mar 8-14;308(5955):199-201 PMID: 6366574
  59. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.
    Cell. 1984 Aug;38(1):119-26 PMID: 6088057
  60. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
    Mol Cell Biol. 1984 Sep;4(9):1689-94 PMID: 6092932
  61. Sequential expression of protooncogenes during lectin-stimulated mitogenesis of normal human lymphocytes.
    Proc Natl Acad Sci U S A. 1986 Jun;83(11):3982-6 PMID: 3012540
  62. The myc oncogene: its role in transformation and differentiation.
    Annu Rev Genet. 1986;20:361-84 PMID: 3028245
  63. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
    Anal Biochem. 1987 Apr;162(1):156-9 PMID: 2440339
  64. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  65. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.
    Genes Dev. 1992 Jul;6(7):1143-52 PMID: 1628822
  66. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas.
    Science. 1992 Jul 10;257(5067):212-4 PMID: 1378649
  67. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors.
    Cancer Res. 1992 Aug 1;52(15):4273-6 PMID: 1638540
  68. Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
    Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491-5 PMID: 1323840
  69. Myc and Max proteins possess distinct transcriptional activities.
    Nature. 1992 Oct 1;359(6394):426-9 PMID: 1406956
  70. Apoptotic cell death induced by c-myc is inhibited by bcl-2.
    Nature. 1992 Oct 8;359(6395):552-4 PMID: 1406975
  71. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
    Cell. 1992 Nov 13;71(4):587-97 PMID: 1423616
  72. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.
    Mol Cell Biol. 1992 Dec;12(12):5581-92 PMID: 1448088
  73. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
    EMBO J. 1992 Dec;11(13):5013-20 PMID: 1464323
  74. Wild-type p53 binds to the TATA-binding protein and represses transcription.
    Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12028-32 PMID: 1465435
  75. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
    Mol Cell Biol. 1993 Jan;13(1):301-6 PMID: 8417333
  76. mdm2 expression is induced by wild type p53 activity.
    EMBO J. 1993 Feb;12(2):461-8 PMID: 8440237
  77. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene.
    Nucleic Acids Res. 1993 Jan 25;21(2):345-50 PMID: 8441640
  78. Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.
    Mol Cell Biol. 1993 Apr;13(4):2432-40 PMID: 8455620
  79. Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3216-20 PMID: 8386367
  80. Differential modulation of cyclin gene expression by MYC.
    Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3685-9 PMID: 8386381
  81. p53 is required for radiation-induced apoptosis in mouse thymocytes.
    Nature. 1993 Apr 29;362(6423):847-9 PMID: 8479522
  82. p53 and DNA polymerase alpha compete for binding to SV40 T antigen.
    Nature. 1987 Oct 1-7;329(6138):456-8 PMID: 3309672
  83. A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas.
    Cell. 1988 Jan 29;52(2):185-95 PMID: 3277717
  84. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
    Mol Cell Biol. 1988 Feb;8(2):531-9 PMID: 2832726
  85. The c-myc protein is constitutively expressed at elevated levels in colorectal carcinoma cell lines.
    Oncogene. 1988 Apr;2(4):367-78 PMID: 3283655
  86. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1.
    Proc Natl Acad Sci U S A. 1988 Jul;85(14):5146-50 PMID: 2839831
  87. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.
    J Virol. 1989 Feb;63(2):739-46 PMID: 2642977
  88. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.
    Science. 1989 Apr 14;244(4901):217-21 PMID: 2649981
  89. Characterization of the human p53 gene promoter.
    Mol Cell Biol. 1989 May;9(5):2163-72 PMID: 2664471
  90. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.
    Mol Cell Biol. 1989 Sep;9(9):3982-91 PMID: 2476668
  91. Mouse p53 blocks SV40 DNA replication in vitro and downregulates T antigen DNA helicase activity.
    Oncogene. 1988 Oct;3(4):405-13 PMID: 2856250
  92. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.
    Proc Natl Acad Sci U S A. 1990 Aug;87(16):6166-70 PMID: 2143581
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
1994-12-00
Pages
7805-15
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC359320
Subset
IM
Grants
NCI NIH HHS · 1 R29 CA59986 · United States
NCRR NIH HHS · S07 RR07160 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]